Brean Capital Maintains Buy On Repros, $41 PT
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a price target of $41.00.
Aschoff noted, “The FDA converted Repros’ end-of-Phase-3 into a Type C meeting rather than the originally communicated Type B meeting. This unfortunately means that the FDA believes that it does not have sufficient data in its possession to advise Repros on how to file its NDA. In defense of the company, the FDA did not yet have a synopsis of the one year safety results due out any day now, nor did the FDA have the drug-drug interaction study results, back when the company filed its briefing documents. It is difficult to tell if the FDA will accept whatever Repros gives them and allow it to at least functionally switch the Type C meeting back to a Type B meeting. Given the recent testosterone therapy AdComm panel, we do not believe that investors will optimistically eye this recent development for Androxal, and instead will review it as a signal that the FDA does not wish to entertain secondary hypogonadism as a disease indication. The press release strongly presumes that the FDA has received this delinquent information already, at a point in time after the briefing documents were filed, but it does not explicitly say so. We can only hope that the FDA will fully consider anything it receives from Repros prior to November.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 12.9% and a 60.7% success rate. Aschoff has a -16.8% average return when recommending RPRX, and is ranked #131 out of 3353 analysts.